



Molecular Pathways in Metastasis of Lung Cancer

Guest Editor:

Dr. Hanibal Bohnenberger

Institute of Pathology, University
Medical Center Göttingen,
Robert-Koch-Straße 40, 37075
Göttingen, Germany

Deadline for manuscript
submissions:

closed (31 January 2025)

Message from the Guest Editor

Dear Colleagues,

Lung cancer is the leading cause of cancer related death worldwide. In addition to the histological classification into mainly non-small cell adenocarcinomas and squamous cell carcinomas and small cell lung carcinomas, the growing understanding of oncogenic molecular pathways has led to a pronounced diversification of therapeutic options and thus to a significant improvement in the prognosis of patients. In particular, however, the pronounced tendency to develop distant metastases, especially in the brain, liver, bones and adrenal gland, severely limits the long-term prognosis of affected patients.

In this special issue, the molecular oncogenic pathways in lung cancer metastases will be highlighted from the perspective of basic, translational and clinical research with the overall goal of improving the use of existing therapeutics and identifying new potential drug targets.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)